Oric Pharmaceuticals (4TZ) Price & Analysis

1 Followers

4TZ Stock Chart & Stats

€11.35

€1.07(11.49%)

At close: Jul 24 4:00 PM EDT

€11.35

€1.07(11.49%)

Day’s Range― - ―

52-Week Range€6.10 - €12.33

Previous CloseN/A

Volume700.00

Average Volume (3M)0.00

Market Cap

€1.11B

Enterprise Value€908.34M

Total Cash (Recent Filing)€264.76M

Total Debt (Recent Filing)€3.33M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Nov 09, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.35

Shares Outstanding103,652,660

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-6.30

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€20.33

Price Target Upside79.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-1.34

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Substantial Equity BaseVery low leverage reduces financial risk and preserves flexibility while ORIC funds research and development. The sizable equity base provides support for continued investment in its clinical pipeline and gives management more options than a heavily indebted biotech during development.

Pipeline Targets Treatment ResistanceA focus on mechanisms of treatment resistance addresses a significant clinical problem for patients whose tumors no longer respond to targeted therapies. If development succeeds, this positioning could support differentiated products and a meaningful role in oncology care.

Equity Plan Supports Hiring And Potential M&AExpanded inducement capacity gives ORIC a flexible tool to recruit specialized talent and potentially integrate acquisition targets. That flexibility can support pipeline execution and organizational growth, while the plan’s Nasdaq-compliant structure reinforces consistent governance around awards.

Bears Say

No Revenue GenerationThe absence of revenue means ORIC has not yet demonstrated commercial product demand or an operating model that can fund itself. This limits visibility into future margins and increases dependence on successful clinical development before meaningful business cash generation can begin.

Widening Net LossesWidening losses indicate that spending remains high relative to the company’s current stage and that profitability has not yet shown a clear inflection. Continued deterioration can consume capital faster, reduce financial flexibility, and increase the funding needed before revenues materialize.

Persistent Negative Cash FlowRecurring cash outflows show that ORIC cannot currently finance operations internally and likely depends on external funding until revenues emerge. Although free-cash-flow growth improved versus the prior period, the absolute burn remains substantial and may create future financing or dilution pressure.

Oric Pharmaceuticals News

Oric Pharmaceuticals participates in a conference call with JPMorgan

JPMorgan discusses Enozertinib, (formerly known as ORIC-114), with management on a conference call to be held on October...

6d ago

ORIC

Closing Bell Movers: Option Care Health up over 20% on takeover interest

Broad-based strength in the mega-cap tech space – in spite of continued upward pressure in Treasury yields –...

7d ago

DRS

NEO

Oric Pharmaceuticals enters pact with Cancer Research UK to advance ORIC-259

Oric Pharmaceuticals (ORIC) announced an agreement with Cancer Research UK to advance a potential CIP2A-targeted therapy into clinical...

7d ago

ORIC

Oric Pharmaceuticals initiated with an Outperform at Leerink

Leerink initiated coverage of Oric Pharmaceuticals (ORIC) with an Outperform rating and $26 price target Published first on...

7d ago

ORIC

Oric Pharmaceuticals initiated with a Buy at BTIG

BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target....

19d ago

PFE

ORIC

Oric Pharmaceuticals initiated with a Buy at BTIG

BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target...

19d ago

ORIC

Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial

Bayer AG ($BAYRY), Oric Pharmaceuticals Inc ($ORIC) announced an update on their ongoing clinical study. Himalayas-1 pushes Bayer...

1M ago

ORIC

Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $27 from $25...

2M ago

ORIC

ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside

In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a...

2M ago

ORIC

Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c)

“The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially...

2M ago

ORIC

Oric Pharmaceuticals Expands Inducement Equity Incentive Plan

Oric Pharmaceuticals ( ($ORIC) ) has shared an update. On July 28, 2026, ORIC Pharmaceuticals’ board approved an...

2M ago

ORIC

Oric Pharmaceuticals initiates Himalayas-1 trial

Oric Pharmaceuticals (ORIC) announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic...

3M ago

ORIC

Oric Shareholders Approve Equity Plan, Governance Measures

Oric Pharmaceuticals ( ($ORIC) ) just unveiled an announcement. On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an...

4M ago

ORIC

Oric Pharmaceuticals resumed with a Buy at Stifel

Stifel analyst Laura Prendergast resumed coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $14 price target...

4M ago

ORIC

4TZ FAQ

What was Oric Pharmaceuticals’s price range in the past 12 months?

Oric Pharmaceuticals lowest stock price was €6.10 and its highest was €12.32 in the past 12 months.

What is Oric Pharmaceuticals’s market cap?

Oric Pharmaceuticals’s market cap is €1.11B.

When is Oric Pharmaceuticals’s upcoming earnings report date?

Oric Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 28 days.

How were Oric Pharmaceuticals’s earnings last quarter?

Oric Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported -€0.339 earnings per share for the quarter, missing the consensus estimate of -€0.32 by -€0.019.

Is Oric Pharmaceuticals overvalued?

According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oric Pharmaceuticals pay dividends?

Oric Pharmaceuticals does not currently pay dividends.

What is Oric Pharmaceuticals’s EPS estimate?

Oric Pharmaceuticals’s EPS estimate is -0.34.

How many shares outstanding does Oric Pharmaceuticals have?

Oric Pharmaceuticals has 103,652,660 shares outstanding.

What happened to Oric Pharmaceuticals’s price movement after its last earnings report?

Oric Pharmaceuticals reported an EPS of -€0.339 in its last earnings report, missing expectations of -€0.32. Following the earnings report the stock price went up 23.37%.

Which hedge fund is a major shareholder of Oric Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:4TZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oric Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-35.35%

Trailing 12-Months

Asset Growth

16.67%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Oric Pharmaceuticals (4TZ) Earnings & Revenues

Historic Earnings Reports

4TZ Stock 12 Month Forecast

Average Price Target

€20.33

▲(79.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","10":"€10","15":"€15","20":"€20","25":"€25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.09761151,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.32926073888889,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€20.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.49505782,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10,15,20,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.605,12.565970116153846,13.526940232307693,14.487910348461538,15.448880464615385,16.40985058076923,17.370820696923076,18.33179081307692,19.29276092923077,20.253731045384615,21.21470116153846,22.17567127769231,23.136641393846155,{"y":24.09761151,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.605,12.27609697991453,12.947193959829061,13.618290939743591,14.289387919658122,14.960484899572652,15.63158187948718,16.30267885940171,16.97377583931624,17.64487281923077,18.3159697991453,18.98706677905983,19.65816375897436,{"y":20.32926073888889,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.605,11.673465986153847,11.741931972307693,11.81039795846154,11.878863944615384,11.94732993076923,12.015795916923077,12.084261903076923,12.15272788923077,12.221193875384616,12.28965986153846,12.358125847692307,12.426591833846153,{"y":12.49505782,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.986,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.146,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.67,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.85,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.605,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >